Clinical Trial Update: A Phase 1/2 Study of T-cell Expressing a Novel CD19 Chimeric-Antigen Receptor (SHB-02-CD19) in Patients With CD19-expressing B-cell Malignancies [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial update for SHB-02-CD19, a novel CD19-directed CAR-T therapy, in CD19-expressing B-cell malignancies; recruitment not yet started.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• SHB-02-CD19

Snippet

Sponsor: Sheba Medical Center | Conditions: B Cell Malignancies, Acute Lymphobkastic Leukemia | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING